"Vitality Biopharma Inc filed an international patent application in March of 2017 that describes compounds discovered to be effective in a drug screening model of neural repair. The underlying patent rights are based on work performed by the Myelin Repair Foundation (MRF), a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis. Researchers discovered several investigational and FDA-approved drugs that are useful in effecting remyelination, a form of nervous system regeneration. The discoveries included a compound called Cannabidiol (CBD), that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. As a result, Vitality Biopharma has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders."
Full story at insiderfinancial.com/vitali...